Find my Biogen Inc. 401(k) plan

Biogen Inc. is a global biopharmaceutical company headquartered in Cambridge, Massachusetts that was founded in 1978 with the mission of using cutting-edge science to discover and develop innovative therapies for serious neurological diseases. Developing treatments based on human genetic data has been driving its research since its inception, and over the years it has established itself as a leader in gene therapy, biologicals and specialty therapeutics. Biogen’s core therapeutic focus consists of various diseases ranging from multiple sclerosis, Parkinson’s disease and Duchenne muscular dystrophy; to Alzheimer's and ALS through intense research and development efforts invested in innovation since 1983. It is listed on the NASDAQ stock exchange under the ticker symbol BIIB, with annual revenue exceeding $11 billion during 2020. With new clinical tests yielding promising results for therapeutic candidates every year, along with strategic acquisitions expanding its product pipeline portfolio and an unwavering commitment to research excellence – Biogen stands out among industry peers offering hope for many suffering from neurodegenerative conditions.